The role of the orphan G protein-coupled receptor 37 (GPR37) in multiple myeloma cells.
暂无分享,去创建一个
Song He | Jie Tang | Chun Cheng | Xiaohong Xu | Xiaojing Yang | Xiaohong Xu | Chun Cheng | Yuchan Wang | Song He | Jie Tang | Xiaojing Yang | Xianting Huang | Yuchan Wang | Xianting Huang | Xun Nan | Xinghua Zhu | Li Yao | Xinxiu Wang | Xinxiu Wang | Xinghua Zhu | Li Yao | Xun Nan
[1] Hermann Einsele,et al. Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma , 2012, British journal of haematology.
[2] C. Chung,et al. Fibronectin-mediated adhesion rescues cell cycle arrest induced by fibroblast growth factor-1 by decreased expression of P21cip/waf in human chondrocytes , 2005, In Vitro Cellular & Developmental Biology - Animal.
[3] W. Dalton,et al. Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell Lines , 1999 .
[4] R. Kerbel,et al. Impact of the cyclin–dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents , 1996, Nature Medicine.
[5] C. Beam,et al. Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells. , 2006, Cancer research.
[6] C. Croce,et al. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25–q27 , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[7] B. Aggarwal,et al. Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model (Molecular Cancer Therapeutics (2009) 8, (959-970)) , 2009 .
[8] C. Lacombe,et al. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma , 2002, Oncogene.
[9] R. Kerbel,et al. Adhesion-dependent multicellular drug resistance. , 1999, Anti-cancer drug design.
[10] W. Dalton,et al. Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR. , 2001, Molecular cancer therapeutics.
[11] L. Pallanck,et al. Parkin A Multipurpose Neuroprotective Agent? , 2003, Neuron.
[12] P. Tan,et al. Parkin Enhances the Expression of Cyclin-dependent Kinase 6 and Negatively Regulates the Proliferation of Breast Cancer Cells* , 2010, The Journal of Biological Chemistry.
[13] N. Munshi,et al. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. , 2006, Cancer research.
[14] W. Dalton,et al. Mechanisms Associated with cell Adhesion Mediated Drug Resistance (CAM-DR) in Hematopoietic Malignancies , 2004, Cancer and Metastasis Reviews.
[15] John Calvin Reed,et al. The AKT kinase is activated in multiple myeloma tumor cells. , 2001, Blood.
[16] R. Kyle,et al. Drug therapy: Multiple myeloma , 2004 .
[17] W. Dalton,et al. Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death , 2003, Oncogene.
[18] D. Katenkamp,et al. Intercellular substances in Hodgkin's lymphomas. Ultrastructural investigations. , 1978, Virchows Archiv A Pathological Anatomy and Histology.
[19] T. Satou,et al. Blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathways by statins reduces the expression of bFGF, HGF, and TGF-β as angiogenic factors in mouse osteosarcoma. , 2011, Cytokine.
[20] Y. Shiozawa,et al. Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironment. , 2010, Blood.
[21] R. Jove,et al. Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. , 2009, Cancer research.
[22] A. Cress,et al. Acquisition of Resistance toward HYD1 Correlates with a Reduction in Cleaved α4 Integrin Expression and a Compromised CAM-DR Phenotype , 2011, Molecular Cancer Therapeutics.
[23] A. McBride,et al. Proteasome inhibitors in the treatment of multiple myeloma , 2013, Expert review of anticancer therapy.
[24] W. Dalton,et al. Adhesion to fibronectin via β1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR) , 2000, Oncogene.
[25] B. Aggarwal,et al. Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model , 2009, Molecular Cancer Therapeutics.
[26] G. Tocchini-Valentini,et al. Absence of the GPR37/PAEL receptor impairs striatal Akt and ERK2 phosphorylation, ΔFosB expression, and conditioned place preference to amphetamine and cocaine , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[27] G. Tocchini-Valentini,et al. Molecular cloning and chromosomal localization of the mouse Gpr37 gene encoding an orphan G-protein-coupled peptide receptor expressed in brain and testis. , 1998, Genomics.
[28] G. Tocchini-Valentini,et al. Altered dopamine signaling and MPTP resistance in mice lacking the Parkinson's disease-associated GPR37/parkin-associated endothelin-like receptor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[29] S. Lonial,et al. PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma. , 2007, Future oncology.
[30] N. Hattori,et al. An Unfolded Putative Transmembrane Polypeptide, which Can Lead to Endoplasmic Reticulum Stress, Is a Substrate of Parkin , 2001, Cell.
[31] W. Dalton,et al. Adhesion-Mediated Intracellular Redistribution of c-Fas-Associated Death Domain-Like IL-1-Converting Enzyme-Like Inhibitory Protein-Long Confers Resistance to CD95-Induced Apoptosis in Hematopoietic Cancer Cell Lines1 , 2002, The Journal of Immunology.
[32] W. Dalton,et al. Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas. , 2006, Blood.
[33] Hermann Einsele,et al. Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival. , 2011, Blood.
[34] Shaji K. Kumar,et al. Thalidomide and lenalidomide in the treatment of multiple myeloma. , 2006, European journal of cancer.
[35] H. Müller-Hermelink,et al. Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma. , 2008, Blood.
[36] Kenneth C. Anderson,et al. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets , 2007, Nature Reviews Cancer.
[37] P. L. Bergsagel,et al. Advances in biology of multiple myeloma: clinical applications. , 2004, Blood.
[38] P. Richardson,et al. Multiple myeloma , 2009, The Lancet.
[39] M. Levrero,et al. Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. , 2008, Blood.
[40] N. Halama,et al. The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications , 2011, British journal of haematology.
[41] S. Jagannath,et al. The current status and future of multiple myeloma in the clinic. , 2010, Clinical lymphoma, myeloma & leukemia.
[42] Charles P. Lin,et al. Defining the role of TORC1/2 in multiple myeloma. , 2011, Blood.
[43] Jin Han,et al. CD40 stimulation induces vincristine resistance via AKT activation and MRP1 expression in a human multiple myeloma cell line. , 2012, Immunology letters.